信迪利单抗、贝伐珠单抗联合含铂双药化疗治疗EGFR-TKI耐药NSCLC患者的疗效及安全性

Efficacy and safety of sintilimab and bevacizumab combined with platinum-containing dual drug chemotherapy in the treatment of patients with EGFR-TKI resistant NSCLC

目的 探讨信迪利单抗、贝伐珠单抗联合含铂双药化疗治疗表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKI)耐药非小细胞肺癌(NSCLC)患者的疗效及安全性。方法EGFR-TKI耐药的NSCLC患者44例随机分为两组。治疗组(22例)采用信迪利单抗、贝伐珠单抗联合含铂双药化疗;对照组(22例)仅采用含铂双药化疗。比较两组治疗后的临床疗效、中位无进展生存期(mPFS)及药物不良反应发生情况。结果 治疗组客观缓解率和疾病控制率均高于对照组(63.64%vs. 31.82%和90.91%vs. 63.64%)(P<0.05)。治疗组患者mPFS为6.7个月,长于对照组的3.9个月(P<0.05)。两组治疗后乏力发生情况有统计学差异(P<0.05),其他不良反应发生情况比较差异无统计学意义(P>0.05)。结论 与仅采用含铂双药化疗比较,加用信迪利单抗、贝伐珠单抗能增强对EGFR-TKI耐药NSCLC患者的疗效,延长mPFS,且不良反应可耐受。

Objective To investigate the clinical efficacy and safety of sintilimab and bevacizumab combined with platinum-containing dual drug chemotherapy in the treatment of the patients with epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor(TKI)resistant nonsmall cell lung cancer(NSCLC).Methods Forty-four patients with EGFR-TKI resistant NSCLC were randomly divided into two groups with 22cases each.The patients in group A received sintilimab and bevacizumab combined with platinum-containing dual drug chemotherapy and those in group B received only platinum-containing dual drug chemotherapy.The clinical efficacy,median progression-free survival(mPFS)and adverse reactions were compared between the two groups.Results The objective remission rate and disease control rate(63.64%vs.31.82%and 90.91%vs.63.64%)were higher in group A than those in group B(P<0.05).The mPFS was longer in group A than that in group B(6.7months vs.3.9months)(P<0.05).There was statistical difference in the occurrence of fatigue after treatment between the two groups(P<0.05),and there were no statistical differences in the other adverse reactions between the two groups(P>0.05).Conclusion Compared with platinum-containing dual-drug chemotherapy alone,the addition of sintilimab and bevacizumab can enhance the efficacy and prolong mPFS with tolerable adverse reactions in EGFRTKI resistant NSCLC patients.